Skip to main content
logo
CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
8.06
-0.29 (-3.47%)
Oct 28, 2025, 4:00 PM EDT - Market closed

Company Description

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors.

The company’s drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies.

It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals logo
CountryUnited States
Founded2017
IPO DateNov 8, 2019
IndustryBiotechnology
SectorHealthcare
Employees5
CEOJohn Climaco

Contact Details

Address:
2100 West Loop South, Suite 900
Houston, Texas 77027
United States
Phone800-946-9185
Websitecnspharma.com

Stock Details

Ticker SymbolCNSP
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$4.00
CIK Code0001729427
CUSIP Number18978H508
ISIN NumberUS18978H5081
Employer ID82-2318545
SIC Code2834

Key Executives

NamePosition
John Michael Climaco Esq., J.D.Chief Executive Officer, President and Director
Christopher S. Downs CPA, CTP, FP&AChief Financial Officer
Dr. Sandra L. Silberman M.D., Ph.D.Chief Medical Officer
Dr. Donald H. Picker Ph.D.Chief Science Officer

Latest SEC Filings

DateTypeTitle
Oct 28, 2025ARSFiling
Oct 24, 2025DEF 14AOther definitive proxy statements
Oct 10, 2025PRE 14AOther preliminary proxy statements
Sep 19, 2025424B5Filing
Aug 14, 2025SCHEDULE 13GFiling
Aug 14, 202510-QQuarterly Report
Jul 22, 20258-KCurrent Report
Jul 15, 20258-KCurrent Report
May 15, 202510-QQuarterly Report
May 15, 20258-KCurrent Report
View All SEC Filings